Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
43.74%
operating margin TTM
54.32%
revenue TTM
793.78 Million
revenue per share TTM
6.43$
valuation ratios | |
|---|---|
| pe ratio | 16.73 |
| peg ratio | 1.23 |
| price to book ratio | 20.43 |
| price to sales ratio | 7.15 |
| enterprise value multiple | 9.08 |
| price fair value | 20.43 |
profitability ratios | |
|---|---|
| gross profit margin | 80.8% |
| operating profit margin | 54.32% |
| pretax profit margin | 54.87% |
| net profit margin | 43.74% |
| return on assets | 21.52% |
| return on equity | 138.37% |
| return on capital employed | 28.66% |
liquidity ratio | |
|---|---|
| current ratio | 7.80 |
| quick ratio | 6.78 |
| cash ratio | 0.83 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 265.61 |
| operating cycle | 376.50 |
| days of payables outstanding | 19.19 |
| cash conversion cycle | 357.31 |
| receivables turnover | 3.29 |
| payables turnover | 19.02 |
| inventory turnover | 1.37 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.73 |
| debt equity ratio | 4.14 |
| long term debt to capitalization | 0.81 |
| total debt to capitalization | 0.81 |
| interest coverage | 30.48 |
| cash flow to debt ratio | 0.32 |
cash flow ratios | |
|---|---|
| free cash flow per share | 3.71 |
| cash per share | 4.72 |
| operating cash flow per share | 3.79 |
| free cash flow operating cash flow ratio | 0.98 |
| cash flow coverage ratios | 0.32 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 44.79 |
Frequently Asked Questions
When was the last time Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported earnings?
Halozyme Therapeutics, Inc. (HALO) published its most recent earnings results on 31-10-2024.
What is Halozyme Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s trailing twelve months ROE is 138.37%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Halozyme Therapeutics, Inc. (HALO) currently has a ROA of 21.52%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did HALO's net profit margin stand at?
HALO reported a profit margin of 43.74% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is HALO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.80 in the most recent quarter. The quick ratio stood at 6.78, with a Debt/Eq ratio of 4.14.